ICH Good Clinical Practice (GCP) for Certified Clinical Research Coordinator (CCRC) Practice Exam

These questions are part of the practice quiz. Start practicing

• Before entering an agreement with an investigator, what should the sponsor provide?
• In Phase I, pharmacokinetic studies may be conducted in which subjects?
• Which term is defined as a printed, optical, or electronic document designed to record all protocol-required information to be reported to the sponsor on each trial subject?
• When may the investigator implement a deviation without prior IRB/IEC approval?
• Upon completion, what should be provided to the IRB/IEC?
• If changes significantly affect the conduct of the trial or increase risk to subjects, how should the investigator report?
• Who is primarily responsible for summarizing safety data in the clinical report?
• Which statement best describes the documentation of trial finances?
• Which element describes the route of administration, dosage, dosage regimen, and treatment periods?
• What documentation should be provided to sponsor and IRB/IEC if termination occurs without sponsor agreement?
• When a death is reported in a clinical trial, what should the investigator provide to the sponsor and the IRB/IEC?
• Which statement best describes the purpose of subject inclusion criteria in a clinical trial?
• Which document describes the written description of a change to the protocol?
• What must be included in informing the subject about the trial?
• Which statement correctly reflects confidentiality of records in publications?
• What is required to protect the confidentiality of records that could identify subjects?
• During the clinical conduct of the trial, which category includes all documents required in the initial phase plus the following?
• What should be described when defining response variables?
• Which of the following is an objective of the ICH safety guidance?
• Who should vote on trial-related matters?
• Which topic outlines how variables are chosen and how data are collected?
• Which document is used to document the financial agreement between the investigator/institution and the sponsor for the trial?
• Post-study events refer to serious adverse events that occurred after completion of a clinical study. In such cases, who is typically responsible for reporting to the sponsor?
• Which document records that trial procedures were reviewed with the investigator and the investigator's trial staff?
• Which statement is true about voluntary participation and withdrawal?
• What must be provided to the IRB/IEC to obtain its favorable opinion?
• Which statement about access to source data should be included in the protocol or written agreement?
• In selecting a control group, which statement best describes acceptable comparisons?
• What is the purpose of maintaining a system for retrieving investigational products and documenting retrieval?
• Which term refers to the laws and regulations addressing the conduct of clinical trials of investigational products?
• Which design typically involves conducting trials at more than one site to gather diverse data?
• When new safety information becomes available during a trial, who must be informed of this information?
• Which element defines how safety data are collected and reported?
• Which item provides the description of the population to be studied in the context of Background Information?
• Which term best describes the formal opinion issued by an Independent Ethics Committee regarding trial ethics and participant safety?
• Which event would not typically be classified as a Serious Adverse Event?
• Who should retain sponsor-specific essential documents pertaining to the trial?
• The Therapeutic Use category is associated with which of the following?
• Which action relates to the investigational product and is a monitor's responsibility?
• Dose-response relationships can be evaluated in which phases of development?
• Which term describes the set of activities designed to ensure the trial's quality by monitoring compliance and processes, not by data itself?
• IRB/IEC should obtain information about payments to and compensation available to subjects.
• Which statement best describes an audit in clinical trials?
• Which document confirms that the site is suitable for the trial?
• Who is permitted to vote on trial-related matters within an IRB/IEC?
• What does SUSAR stand for?
• The ethical principles underlying GCP and informed consent trace their origin to which document?
• What is GMP's main aim for IP manufacturing?
• What document records site visits by, and findings of, the monitor?
• If the sponsor terminates or suspends a trial, what is the investigator's obligation?
• During and after participation, what is the investigator's obligation regarding adverse events and significant laboratory values?
• If a health issue is unrelated to the trial drug, how is it usually categorized?
• What must a monitoring report include after each site visit?
• Which item is NOT a required element of IRB/IEC confirmation of review?
• Early nonclinical safety studies should provide information to support which of the following, EXCEPT?
• Which document includes original records related to the trial, to medical treatment, and history of the subject and substantiates the trial data?
• What information must be described about investigational products?
• When a trial is terminated or suspended, which parties should be informed promptly and given reasons?
• What must be described and justified regarding the investigational product?
• Which are the objectives associated with Therapeutic Exploratory studies?
• Interim or annual reports are provided to which parties?
• What is required when protocol deviations occur?
• Before initiating a trial, which approvals must the investigator obtain from the IRB/IEC?
• The sponsor's audit plan and procedures should be guided by which factors?
• Which term describes all noxious and unintended responses to a medicinal product related to any dose?
• How should the investigational product(s) be stored?
• Which activity is a monitor's responsibility to ensure the trial is conducted and documented properly?
• Which statement best represents a core purpose of the ICH E8 document?
• Which scenario would be categorized as an 'Other Observations' item?
• Which item is not included in the Introduction content?
• The sponsor should utilize qualified individuals throughout all stages to do what?
• What is the primary rationale for using multiple analysis sets?
• Which term refers to an independent body responsible for protecting rights, safety, and well-being of human subjects by reviewing, approving, and providing continuing review of trial protocols and informed consent documents?
• What describes the procedures for tracking the investigational products, including placebos and comparators?
• Which action should the investigator take if a trial is prematurely terminated or suspended?
• Which topics are encompassed by the Estimation, Confidence Intervals and Hypothesis Testing section?
• Which option lists the acceptable locations for documenting shipping records for investigational products?
• The physical and mental integrity of the subjects participating in a clinical trial is described as what?
• In the Phase IV framework, which category specifically covers Studies of Drug Metabolites?
• What is a primary purpose of Phase IV studies?
• In the context of Investigational Medicinal Products, which aspect should be well characterized in formulations used in clinical trials?
• Which factor is essential when selecting auditors?
• Adverse events and/or laboratory abnormalities identified as critical to safety evaluations should be reported to the sponsor according to what?
• What does Direct Access refer to in the context of clinical trials?
• Which statement best describes the sponsor's duty regarding costs of treatment for trial-related injuries?
• What action ensures compliance with GCP regarding oversight?
• Which term refers to the judgement and/or advice provided by an Independent Ethics Committee (IEC)?
• If a subject cannot read, what is required during the consent discussion?
• In blinded trials, what should the coding system include?
• What type of review does the IRB/IEC perform for trials?
• Quality assurance activities require written SOPs. Who is responsible for implementing and maintaining QA/QC systems with written SOPs?
• If data are transformed during processing, what must be possible?
• Which records are required to document the shipment, receipt, disposition, return, and destruction of the investigational product?
• Which statement about the investigational product and protocol is true?
• What document records revisions to normal values/ranges used for medical, laboratory, or technical procedures included in the protocol?
• In trials where enrollment can occur only with the consent of the subject's legally acceptable representative, if the subject is capable, what should occur regarding consent?
• Which trial design randomizes participants to two or more arms, each arm receiving a different treatment?
• Which statement best describes the focus of the Therapeutic Use category?
• Which topic involves evaluating the safety and tolerability of a therapy in a clinical trial?
• What should be described about the population to be studied?
• What is required before initiating a trial regarding Investigator's Brochure?
• Which document contains the objective, design, methodology, and statistical considerations of a trial?
• What term describes the planned and systematic actions to ensure trial activities comply with GCP and regulatory requirements?
• Which of the following best reflects Phase IV objectives related to patient populations?
• Development Methodology in the context of the development plan covers what?
• Who is the person primarily responsible for the proper conduct of the trial at the site?
• What must be provided to show the investigator's qualifications?
• Which term is a person or an organization (commercial, academic, or other) contracted by the sponsor to perform one or more of a sponsor's trial-related duties and functions?
• Which option best describes what the introduction to nonclinical pharmacology should include?
• Which statement accurately describes the staffing and facilities requirement?
• What role do designated medical personnel play in the trial?
• What must be documented regarding data changes to electronic systems?
• Which document records the method for randomization of the trial population?
• Which role is an individual who both initiates and conducts a trial and under whose immediate direction the investigational product is administered to a subject?
• What information should be provided for the clinical laboratories and other medical or technical departments involved in the trial?
• Phase II primary objective?
• Which document contains pharmacology, toxicology, and prior human experience data on the investigational product to support human studies?
• Which trial type has a rationale and design that rests on earlier work, and should have clear and precise objectives, though those objectives may not lead to simple tests?
• Which topic covers handling data gaps and unusual values in data?
• What is a monitor's duty regarding CRF entries and source documents?
• Which term refers to adherence to trial-related requirements and Good Clinical Practice (GCP) requirements?
• Which statements best describes what is subject to expedited reporting for adverse drug reactions?
• Which statement best describes pre-trial regulatory notification?
• Which statement combines the enrollment number and power calculations to justify the trial size?
• For a fatal or life-threatening ADR, the initial notification must include which of the following elements?
• Which two techniques are described as measures to minimize bias in the trial?
• Early nonclinical safety studies should provide information to support which item related to first‑in‑human testing?
• How should study reports be prepared in relation to guidelines?
• Which entity should retain sponsor-specific essential documents related to the trial?
• The term used for the physical and mental well-being of the trial subjects is what?
• What is the primary purpose of expedited SUSAR reporting to regulatory authorities?
• If a trial is prematurely terminated or suspended, what information should be promptly communicated?
• Which document identifies subjects who entered pre-trial screening?
• What is required regarding follow-up information for expedited ADR reports?
• Which statement about sponsor responsibility is true?
• Which description best characterizes study endpoints?
• When any trial-related duties are transferred to a CRO, what must be specified in writing?
• What is the primary purpose of a parallel group design?
• The plan outlining what aspects of a trial are to be evaluated is described by which topic?
• Where are the analysis sets typically defined in a clinical trial protocol?
• Which document updates the Investigator's Brochure during the trial?
• Who is primarily responsible for supplying the investigational product to investigator sites?
• How often should investigators check that each subject is following the instructions for using the investigational product?
• What is the recommended approach when presenting conclusions about efficacy in the summary?
• Which party is responsible for the ongoing safety evaluation of the investigational product?
• In the Phase IV design, what aspect relates directly to safety monitoring?
• The sponsor should update the Investigator's Brochure in which scenario?
• The sponsor should submit to regulatory authorities all safety updates and periodic reports as required by which of the following?
• What should be documented regarding the responsibilities of coordinating and participating investigators before starting the trial?
• Which statement best characterizes the design techniques to avoid bias in clinical trials?
• Before starting the trial, how should regulatory submissions be dated?
• Where should essential documents be located?
• Which term denotes the regulatory framework governing clinical trials of investigational products?
• An individual who participates in a clinical trial, either as a recipient of the investigational product or as a control, is called what?
• Which term is a written evaluation by the sponsor's auditor of the results of the audit?
• Labeling of investigational product(s) must comply with what?
• Which section should include the description of the population to be studied?
• Which documents should the IRB/IEC obtain from the investigator?
• Which of the following describes the Per Protocol Set's components?
• What term describes the pharmaceutical form of an active ingredient or placebo that is tested or used as a reference in a clinical trial?
• Which document is used to document the agreement between the investigator and sponsor to the protocol/amendments and the CRF?
• Data capture and processing in a trial can transfer data from the investigator to the sponsor through which media?
• Who maintains the confidential Subject Identification Code List?
• Which statement describes monitoring guidance for procedures?
• Which item describes the known and potential risks and benefits to human subjects?
• Trials to Show Equivalence or Non-inferiority are divided into two major objective-based categories. What are these two categories?
• Before the clinical phase of the trial commences, what should be documented?
• What is the primary purpose of a sponsor's audit?
• Which statement best describes the broad aim of the development plan for a new drug?
• What is a primary purpose of packaging for the investigational product?
• Sample size adjustment is used to account for what during a trial?
• Which statement best describes medications permitted before and/or during the trial?
• Who should provide Curriculum Vitae and other documents evidencing qualifications of investigators and sub-investigators?
• Surrogate variables are used as reliable predictors of clinical benefit in various indications. Which option matches this idea?
• Who may inspect trial records as part of QA and regulatory oversight?
• Deviations from or changes to the protocol should not be initiated without prior written IRB/IEC approval except in which circumstances?
• Which element describes the trial's design and includes a schematic diagram of its design, procedures, and stages?
• What recruitment capability must the investigator demonstrate for the trial?
• What is the stated general expectation about on-site monitoring in trial monitoring guidance?
• What does statistically controlled sampling in monitoring pertain to?
• Which design typically involves conducting trials across multiple research sites?
• Which aspect must be described about the investigational product to ensure proper administration and traceability?
• What is required regarding the immediate SAE report?
• Which topic covers the set of subjects to be evaluated and the presentation of data?
• Under Investigator-Adequate Resources, what is emphasized?
• The plan for the scope of evaluation in a clinical trial is described by which topic?
• Which statement best describes a monitor's responsibility regarding informed consent?
• Which document specifies the master randomization list?
• Which term refers to an independent data-monitoring committee that may be established by the sponsor to assess at intervals the progress of a clinical trial, the safety data, and the critical efficacy endpoints, and to recommend to the sponsor whether to continue, modify, or stop a trial?
• If the Investigator's Brochure is updated during the trial, what should be done?
• The sponsor should utilize qualified individuals throughout all stages of the trial for which purpose?
• What primarily determines the sample size of a clinical trial?
• Which document records the final accounting of investigational products at the site?
• In a multicenter trial, who is primarily responsible for ensuring standardized data collection across sites?
• Investigators must permit which activities?
• Which entities should the sponsor promptly notify about findings that could affect subject safety, trial conduct, or the continued favorable opinion of the IRB/IEC?
• What information describes the expected duration of subject participation and the sequence of all trial periods?
• Does the protocol specify whether and how replacement of withdrawn subjects may occur?
• Which statement best describes the purpose of Any Other Written Information provided to trial subjects?
• What term refers to the act of overseeing the progress of a clinical trial and ensuring it is conducted, recorded, and reported in accordance with the protocol, SOPs, GCP, and regulatory requirements?
• What documentation should the sponsor obtain regarding IRB/IEC re-approvals or reevaluations?
• Which statement about auditors is correct?
• Global Assessment Variables measure what in a clinical trial?
• Which statement best describes the CRO's QA/QC duties?
• Which term describes adherence to all the trial-related requirements, Good Clinical Practice (GCP) requirements, and the applicable regulatory requirements?
• Which statement about non-therapeutic trials with LAR consent is NOT correct?
• According to GCP guidance, who should the sponsor utilize to supervise the overall conduct of the trial, handle statistics, verify data, conduct statistical analysis, and prepare trial reports?
• Which of the following is explicitly a Phase IV subcategory?
• The extent and nature of monitoring should be based on considerations such as objective, purpose, design, complexity, blinding, size, and endpoints. True or False?
• Which statement ensures site-level enrollment targets are documented for multisite trials?
• Which statement describes ensuring information for trial personnel about protocol and investigational products?
• A unique identifier assigned by the investigator to protect subject identity when reporting trial data is called what?
• When a subject withdraws from the trial, which data should be collected?
• Under what circumstances might multiple primary variables be appropriate?
• Which item defines the safety endpoints to be monitored and how they are measured?
• In a trial protocol, which elements must be explicitly defined as the primary and secondary outcomes to be measured?
• Which option best describes the criterion that ensures staff are qualified for their tasks?
• Which item best demonstrates IRB/IEC compliance with GCP and applicable laws?
• In the Effects in Humans: Introduction, which topics may be included when available?
• What should the investigator ensure about staffing and facilities for the trial?
• Which statement best describes data quality requirements for CRFs and required reports?
• Which statement about the scope of trials is accurate?
• What is the required documentation for informed consent?
• How often should the IRB/IEC conduct continuing review of ongoing trials, considering risk level?
• Which member of the trial team is designated and supervised by the investigator at the trial site to perform critical trial-related procedures and/or to make important trial-related decisions?
• Which statement best describes sponsor's audit purpose?
• Which item summarizes findings from nonclinical studies and clinical trials relevant to the trial?
• Data transformation is typically used to?
• What is the purpose of the sponsor notifying investigators of safety information?
• Which term refers to any investigation in human subjects intended to discover or verify the clinical, pharmacological and/or other pharmacodynamic effects of an investigational product, and/or to identify adverse reactions, and/or to study absorption, distribution, metabolism, and excretion of an investigational product with the object of ascertaining its safety and/or efficacy?
• Financing and insurance provisions should be described where if not addressed in a separate agreement?
• What type of subject identification code should the sponsor use?
• To document that there are written agreements among involved parties, which location is used?
• On request from monitor, auditor, IRB/IEC, or regulatory authority, what should the investigator do?
• Considerations for the Development Plan emphasize which aspect?
• Prior to initiating a trial, what should be defined, established, and allocated?
• Prior to the trial, what must be obtained regarding the consent forms?
• Where is the timing of any planned interim analysis described?
• Which entity is authorized under applicable law to consent on behalf of a prospective subject to participate in the trial?
• In a non-therapeutic trial, who normally must give consent and sign the written informed consent, unless an exception is justified?
• Which topic focuses on the methods for statistical evaluation in a trial?
• Which action is explicitly described as a sponsor responsibility related to stability and retention of the investigational product?
• What is the role of an independent data-monitoring committee (IDMC) in a clinical trial?
• Which term describes signs or diseases temporally associated with the use of a medicinal product?
• What topics should be included in the Effects in Humans: Introduction with respect to pharmacokinetics data?
• Who may be designated to maintain records of the product's delivery to the trial site, the inventory at the site, the use by each subject, and the return to the sponsor or alternative disposition of unused product(s)?
• Which item should be described to ensure proper handling, labeling, and traceability of the investigational product during the trial?
• Which document records that the investigator is informed in a timely manner of relevant information as it becomes available?
• When a subject withdraws due to safety concerns, which data should be documented?
• What edition-related information is suggested to be provided?
• What is the role of randomization in a clinical trial?
• If the investigator terminates or suspends a trial without prior agreement of the sponsor, what is required?
• What is required when data on the CRF is derived from source documents?
• Which term describes the ongoing evaluation of trial progress and subject safety by a monitor, and the reporting of findings to the sponsor?
• Publication policy in GCP should be addressed where if not in a separate agreement?
• Which statement best describes the close-out documentation requirements?
• Which elements are included in the subject withdrawal criteria and procedure?
• Which definition best describes a Serious Adverse Event (SAE) in GCP?
• The responsibility for medical care and medical decisions for trial subjects rests with which professional?
• Interim analyses may lead to early stopping when which conditions are met?
• Which statement best describes subject protection focus in ICH GCP general principles?
• Before starting a trial, which element is most appropriate to be clearly specified in the protocol?
• Which statement correctly describes sponsor auditing procedures?
• Interim analysis and early stopping are used to compare treatment arms with respect to what?
• What is the purpose of reviewing the amount and method of payment to subjects?
• Which of the following best describes what the IRB/IEC review should encompass?
• What should the protocol specify to minimize bias?
• Which statement best describes the handling of changes or corrections to the CRF?
• Data transformation in analysis is used to do what?
• Which term is a description of a study described as a trial conducted in humans that is produced by integrating clinical and statistical descriptions in a single report?
• Which statement best captures the requirement for investigator qualifications?
• What documentation records agreements or significant discussions regarding trial administration, protocol violations, trial conduct, adverse event (AD) reporting?
• To preserve confidentiality, which identification method should be used in SAE reporting?
• Under what circumstances are interim results appropriate to include in the clinical study report?
• What does the IRB/IEC conduct with regard to trials?
• What should the Summary highlight according to the guidelines?
• What is required to ensure timely delivery of the investigational product to investigators?
• What should be included in written information for payment?
• What should the Summary emphasize?
• Which term refers to the original documents, data, and records used during a clinical trial?
• Which term denotes the protection of a sponsor's proprietary information and participant identities from unauthorized disclosure?
• Which document is used to document signatures and initials of all persons authorized to make entries and/or corrections on case report forms?
• The primary aim of protecting clinical trial subjects is to ensure what?
• Which statement best describes the primary variable in a clinical trial?
• In trial documentation, which element identifies the laboratories and other departments involved?
• Which statement best describes IRB/IEC responsibilities?
• Global assessment variables are typically implemented as what kind of scale?
• How should response variables be defined in the protocol?
• Which topic covers subgroups, interactions, and covariates?
• Which term is a committee that a sponsor may organize to coordinate the conduct of a multicenter trial?
• The investigator should comply with the protocol; what is required?
• If the IRB/IEC terminates or suspends its approval, what should the investigator do?
• How should clinical study reports be documented?
• Why might significance levels be adjusted when multiple analyses are performed?
• Why have multiple analysis sets?
• As part of the investigator's written application to the IRB/IEC, what must be provided?
• Which description best captures the essential focus when selecting a dose range in development planning?
• What population is typically used for safety analyses in a GCP-compliant trial?
• To document the existence of the subject and substantiate integrity of trial data collected; to include original documents related to the trial, to medical treatment, and history of subject
• All investigators must conduct the trial in strict compliance with which directive?
• What distinguishes an Adverse Drug Reaction (ADR) from a general Adverse Event (AE)?
• Medical expertise is applied in which area according to the guideline?
• Which information must be specified about treatments for each trial group?
• The design of case report forms (CRFs) in multicenter trials should capture what?
• To monitor adequately, monitors should be thoroughly familiar with which of the following?
• Where are analysis sets defined in a protocol?
• Which item ensures that references to literature and data relevant to the trial are included?
• Which term describes permission to examine records and reports that are important to evaluation of a clinical trial?
• Which bodies have the power to regulate clinical trials?
• Clinical trials should be conducted in accordance with ethical principles originating from which source?
• The nonclinical pharmacology section should include which of the following?
• What ensures that each individual involved in conducting a trial is qualified by education, training, and experience to perform their task?
• Why must the protocol describe dosing schedules and follow-up periods for each treatment group?
• Accrual rate refers to which aspect of a trial?
• The sponsor and the investigator/institution should sign the protocol, or an alternative document, to confirm agreement. What action confirms agreement?
• What is the role of the investigator in IRB/IEC deliberations?
• Which term identifies the formal approval by the IRB to conduct the trial at the site?
• Which statement reflects a data security requirement for electronic data handling?
• After an SAE is reported immediately, what should follow?
• Which term refers to any medical or dental facility where clinical trials are conducted?
• Adverse events reporting timeframe?
• Which term describes an individual responsible for the conduct of the clinical trial at a site?
• Which statement best describes what is involved in establishing the IRB/IEC's formal basis?
• Surrogate variables are used in indications where they are believed to be reliable predictors of clinical benefit. True or false?
• Phase III primary objective?
• What determinations should the sponsor make for the investigational product regarding storage?
• Which items should the sponsor obtain to confirm IRB/IEC review and operation?
• What term describes the act by a regulatory authority of conducting an official review of documents, facilities, records, and related resources for the trial?
• According to the material, the Investigator's Brochure serves to document which of the following?
• Interim or annual reports to regulatory authorities are typically provided by which party?
• In a trial with more than one presentation or use, how should safety reporting be conducted?
• What statement best describes the purpose of direct access to source data and documents in GCP inspections?
• The sponsor should maintain records for which activities related to the investigational product's lifecycle?
• How should the language of the consent information be written?
• Which documents guide the trial design, protocol, and conduct?
• 4.5.1 summarizes which concept?
• Which item must be included in the informed consent discussion and form? 4.8.9 content about risks and benefits etc.
• What is the purpose of Information Given to Trial Subject -- Informed Consent Form?
• Which ICH guideline covers the structure and content of clinical study reports?
• What describes the stopping rules or discontinuation criteria for the trial?
• What is documented by Advertisement for Subject Recruitment?
• Which category requires reporting within 15 calendar days after first knowledge?
• When do Phase IV studies occur in the drug development lifecycle?
• Data handling and record keeping in a GCP trial should ensure which principle?
• Which term describes documents that permit evaluation of the conduct of a study and the quality of the data produced?
• Which statement best describes the 'Considerations for Individual Clinical Trials' category?
• Which of the following is required for an independent data-monitoring committee (IDMC) to effectively operate?
• Group sequential designs are used to facilitate the conduct of interim analyses.
• Which statement best describes the investigator's obligation to communicate with the IRB/IEC?
• Which information is included when discussing storage and handling?
• Which activities are included in the IRB/IEC's responsibilities related to meetings?
• What is true about GMP in relation to investigational product coding and labeling?
• What approach should be implemented to assure the quality of every aspect of the trial?
• What is the primary purpose of the coding in blinded trials?
• Should records identifying the subject be kept confidential and identity remain confidential when results are published?
• Who should permit monitoring and auditing by the sponsor, and inspections by regulatory authorities?
• In Phase I, which objective may be conducted as a secondary objective?
• Individuals whose willingness to volunteer in a clinical trial may be unduly influenced by expectation, benefits associated with participation, or hierarchical retaliation are referred to as what?
• Which entities should sponsor-specific essential documents be retained for in conformance with regulatory requirements?
• How long should sponsor-specific essential documents be retained?
• Which term refers to original documents, data, and records?
• Which two roles are typically responsible for safety data collection and reporting in a trial?
• Which topic focuses on presenting data and identifying the subjects to be evaluated?
• Which statement best describes the role of the investigator regarding monitoring and auditing?
• Which term describes a sponsor-organized group that coordinates the conduct of a multicenter trial?
• What does the term Investigator-Adequate Resources imply?
• What should be done with the observations and findings of auditors?
• Which item is NOT typically considered a key data element for expedited reports of serious adverse reactions?
• Which records document the qualifications of investigators and sub-investigators?
• The subtopic 'Evaluation and Reporting' addresses which aspect of trial data?
• When should IRB/IEC decisions be made?
• Which statement about formulation details is correct?
• A transfer of ownership of trial data should be reported to which entity?
• What is the purpose of providing relevant and current scientific information about the investigational product to the investigator?
• Before informed consent may be obtained, what should the investigator provide?
• Which type of trial is designed to provide firm evidence of efficacy or safety?
• What does the term 'Expectedness' refer to in the context of an ADR?
• What documentation describes shipment dates, batch numbers, and method of shipment for investigational products to enable tracking and accountability?
• If significant formulation changes are made during clinical development, what must be available prior to using the new formulation in clinical trials?
• Which element describes the methods and timing for assessing, recording, and analyzing efficacy parameters?
• Which aspect most directly ensures the scientific integrity and credibility of a clinical trial's data?
• What must be obtained before initiating any protocol deviation?
• What type of trial is designed to show that the investigational product is equivalent to, or not worse than, a reference treatment?
• What should the investigator do for any deviation from approved protocol?
• After reporting a fatal or life-threatening ADR within 7 days, by when should a more complete report typically be provided?
• Regarding randomization and unblinding, which statement is correct?
• Before starting a trial, which statement about IRB approval is correct?
• The Development Plan considerations address which of the following aspects?
• Who is responsible for investigational product accountability at the trial site(s)?
• In GCP, how are efficacy data distinguished from safety data?
• Which principle guides respect for participants and an appropriate risk-benefit assessment in trials?
• What form must agreements between the sponsor and investigator or institution take?
• What documentation identifies the IRB/IEC review and approval and notes the version number and date of documents?
• Which statement should be included in the statistical plan to describe interim analysis timing?
• Prior to supplying investigational product to a trial site, what must the sponsor obtain?
• In GCP trials, what level of significance is commonly used for hypothesis testing?
• What is the sponsor's responsibility regarding site access for monitoring, auditing, and inspection?
• Which term is defined as any untoward medical occurrence in a patient or trial subject administered a pharmaceutical product, regardless of causal relation?
• To document informed consent, which documents are described as used?
• What does the Introduction convey about the product's identity and research rationale?
• How is subject safety addressed in a GCP trial?
• Which document confirms the formal written agreement among the involved parties before the study begins?
• Which statement best describes the focus of the Development Plan Considerations?
• Before initiating a clinical trial, how should foreseeable risks and inconveniences be weighed in relation to anticipated benefits for the subject and society?
• What is the primary purpose of allocating trial-related duties and functions before trial start?
• What expenses information must be included in the consent?
• Which statement best describes sponsor obligation in investigator selection?
• Which topic is addressed by procedures for monitoring subject compliance?
• Blinding aims to limit conscious and unconscious bias in which areas?
• Fatal or life-threatening unexpected ADRs must be reported to regulatory authorities within what timeframe after first knowledge?
• Which topic describes the procedural aspect of submitting expedited ADR reports?
• Informing the subject's primary physician about participation is recommended under what condition?
• Which scenario best illustrates the scope of stopping rules within a trial protocol?
• Under monitoring guidance, which statement correctly describes the 5.18.1 purpose?
• Which statement is a required characteristic of changes or corrections to CRFs?
• Which term describes a procedure in which one or more parties to the trial are kept unaware of the treatment assignment?
• What should the Introduction contain?
• Who should be responsible for all trial-related medical decisions?
• Which actions should be reported promptly to the IRB/IEC?
• Documentation of regulatory authorities' authorization/approvals/notifications required for protocol amendments and other documents should be kept by which parties?
• Which document confirms that all activities required for trial close-out are completed and copies of essential documents are filed?
• Which of the following should the IRB/IEC obtain to verify investigator qualifications?
• Which item specifies the timing of any planned interim analysis?
• Which topic encompasses trial monitoring and interim analyses?
• Who must notify the sponsor of serious adverse events and related reports?
• Which items should be included in the investigational product accountability records?
• Which statement correctly describes the relationship between Adverse Drug Reaction and Adverse Event?
• Essential documents retention extension: It may be longer if required by what?
• Which document demonstrates competence of the facility to perform required tests and support reliability of results?
• What is required before enrolling any subject in a trial?
• What is the primary purpose of documenting normal values/ranges for medical, laboratory, or technical procedures included in the protocol?
• Phase II typically starts with initiation of studies in which population?
• What best describes the investigator's obligation to IRB/IEC communication?
• In describing the investigational product's physical, chemical, and pharmaceutical properties, which item must be included?
• What is the compilation of clinical and nonclinical data on the investigational products relevant to the study called?
• Which section addresses the reporting of reactions associated with active comparator or placebo treatment?
• What is the requirement regarding those who assist with the trial?
• Which body must approve the inclusion of subjects for whom consent may be provided by a legally acceptable representative in non-therapeutic trials?
• Which document describes how, in an emergency, the identity of blinded investigational product can be revealed without unblinding remaining subjects?
• Which documentation category tracks certification, accreditation, QC, external QA, or other validation of procedures used in the protocol?
• What must be included in the justification for sample size?
• Post-study adverse events are typically reported by the investigator to the sponsor. true or false?
• Which statement about source data verification is correct?
• Where should the financial aspects of the trial be documented?
• Who is responsible for the accuracy of the clinical database summary?
• Which statement accurately describes the use of documentation for all subjects who began trial procedures?
• Which statement accurately describes language in the informed consent process regarding waiving legal rights?
• Which data are typically included under safety data in a clinical trial report?
• Which element details the type and duration of the follow-up of subjects after adverse events?
• Under what guideline condition may abbreviated study reports be acceptable?
• The role of attending the informed consent process if the subject or legal representative cannot read is associated with which role?
• Which term describes an investigator assigned the responsibility for the coordination of investigators at different centers participating in a multicenter trial?
• Which document identifies the IRB/IEC approval (dated and documented) of trial related documents?
• What should be done regarding patient compliance in a trial?
• True or False: Phase IV studies begin after drug approval.
• Which statement best describes how information in the Investigator's Brochure should be presented?
• In a Human Pharmacology study, which objective is typically included?
• In SAE reporting, how should subjects be identified?
• If monitoring or auditing identifies serious and persistent noncompliance, what should the sponsor do?
• Who is responsible for selecting investigators/institutions?
• What is the purpose of assigning unique code numbers to the investigational product(s) and to trial subjects?
• In a crossover design, what is a key benefit for treatment comparisons?
• What term refers to detailed, written instructions to achieve uniformity of the performance of a specific function?
• Which design is used to facilitate interim analyses in clinical trials?
• Which term is an investigational or marketed product, or placebo, used as a reference in a clinical trial?
• Which statement about the Independent Data Monitoring Committee (IDMC) is true?
• Informed Consent is defined as
• Which groups are explicitly included under Special Populations in Phase IV guidelines?
• Which trial type is an adequately controlled study in which hypotheses are stated in advance and evaluated to provide firm evidence of efficacy or safety?
• What elements should be included in the Phase IV study design?
• Randomization provides a sound statistical basis for the evaluation of treatment effects. Which option best expresses this?
• Which element should include the power considerations when determining sample size?
• Which statement correctly describes expedited review for minor changes?
• Which action documents that the investigator or authorized staff confirms the observations recorded in the Case Report Form (CRF)?
• Who may request evidence of the investigator's qualifications?
• Expedited safety reports should comply with regulatory requirements and which ICH guideline?
• Annual progress report to whom?
• In multi-center trials, who is responsible for organization and selection of coordinating investigator(s)?
• What factors influence the sample size in a clinical trial?
• Which statement describes the purpose of keeping essential documents post-trial?
• If a single primary variable cannot be selected from multiple measurements, what strategy is recommended?
• Which statement about the Subject Screening Log is true?
• If prior consent of the trial subject or the subject's legally acceptable representative is not possible, what must the IRB/IEC determine?
• Which statement is true about familiarization with the investigational product use?
• Which statement best describes the Per Protocol Set?
• Which element should be included regarding patients who stop treatment prematurely in Phase IV trials?
• Who should retain records of the changes and corrections to CRFs?
• The IRB/IEC should retain all relevant records for a period of at least how long after completion?
• What documentation verifies the qualifications and eligibility of new investigators and/or sub-investigators to conduct the trial?
• Which adverse drug reactions (ADRs) require expedited reporting to all concerned investigators/institutions, IRBs/IEC(s) where required, and regulatory authorities?
• In a multicenter trial, which term refers to a committee organized by a sponsor to coordinate the conduct of the trial?
• After completion or termination, which set of documents should be retained?
• What form should the Investigator's Brochure information take?
• What are the purposes of trial monitoring?
• Why should the Investigator's Brochure be updated?
• True or false: The initial expedited ADR report must identify the patient, the suspect product, the reporting source, and indicate that the event is serious and unexpected with a reasonable suspected causal relationship.
• If a trial-related duty is not transferred to the CRO, who retains that duty?
• When should the written informed consent form and any other written information be revised, and what approval is required before use?
• Which combination best describes the data transfer media used in data capture and processing?
• What is required when transferring any trial-related duty to a CRO?
• The monitor's responsibilities include ensuring that the trial is conducted and documented properly by carrying out activities when relevant. This is described in which section?
• What must be obtained from every subject prior to clinical trial participation?
• Phase IV objectives may include the assessment of which type of parameters?
• Which document covers the decoding procedures for blinded trials?
• What must investigators maintain to demonstrate that subjects were provided the doses specified by the protocol and to reconcile all investigational product(s) received from the sponsor?
• What should the analysis plan consider regarding early withdrawals and protocol violations?
• Outside consultant(s) may be appointed for what purpose?
• Which action ensures data can be recovered in case of system failure?
• The set of data elements (patient initials, suspected medicinal product, other treatments, details of the suspected ADR, details on the reporter, and administrative details) are used for expedited reports to ensure what?
• Which topic describes the evaluation of safety and tolerability?
• Which statement about Multiple Primary Variables is true?
• Which items must the IRB/IEC promptly notify the investigator in writing?
• Which best describes how safety findings should be presented in the final report?
• What is the primary aim of trial monitoring?
• In multicenter trials, what should be provided when investigators collect additional data beyond the core protocol?
• Which is a written description of a change to or formal clarification of a protocol?
• What is the written report from the monitor to the sponsor after each site visit or other trial-related communication called?
• What should the Investigational Brochure describe regarding risks and monitoring?
• Noncompliance with protocol, SOPs, GCP, or regulatory requirements by an investigator or sponsor staff should lead to what action?
• Which statement best distinguishes Quality Control from Quality Assurance in GCP?
• Who should the sponsor designate to advise on trial-related medical questions or problems?
• Which document would you reference to verify the IRB/IEC approval status and its date/version information?
• Which activity describes the IRB/IEC's scheduling and notification responsibilities?
• Before initiating the clinical trial(s), what should the sponsor submit to the appropriate authority(ies)?
• The method and manner of compensation to trial subjects should...
• Which statement best reflects the requirement regarding coercion or undue influence in trial participation?
• Which aspects should the protocol’s analysis plan cover?
• Which documentation should the IRB/IEC consider to assess the investigator's qualifications for a proposed trial?
• Which item is an example of 'Other Observations' in expedited reporting?
• Who should sign off on changes or corrections to CRFs made by sponsor-designated representatives?
• Non-therapeutic trials conducted with consent of a legally acceptable representative should be conducted under which condition?
• Which document demonstrates that regulatory authorities have authorized/approved/notified the protocol prior to initiation of regulatory requirements?
• Which statement best reflects a general principle of ICH GCP regarding subject protection?
• Which term is a written, dated, and signed agreement between two or more involved parties that sets out any arrangements on delegation and distribution of tasks and obligations and, if appropriate, on financial matters?
• Which statement best defines an Adverse Event (AE) in a clinical trial?
• When should the investigator inform the subject about the need for medical care for intercurrent illness(es)?
• Which document is used to determine the expectedness of an ADR?
• Which term describes documentation that allows reconstruction of the course of events?
• The Introduction should provide the general approach to what?
• If the sponsor discontinues clinical development of an investigational product, how long should sponsor-specific essential documents be retained?
• What is the requirement for informing all persons assisting with the trial about the protocol and duties?
• Which statement is true about trial-related injury is required in the consent?
• Exploratory trials should have clear and precise objectives.
• What action should be taken with safety updates and periodic reports?
• What should the investigator maintain regarding significant trial-related duties?
• What should be done with trial-related essential documents after the trial when there are still potential marketing applications?
• Which statement best describes how an IRB/IEC should operate?
• What is the purpose of adjusting significance and confidence levels?
• If the trial is blinded, what must the investigator do in the event of any premature unblinding?
• Which statement is true about confidentiality and ongoing information for trial subjects?
• What is the purpose of pre-specifying the statistical analysis in a protocol?
• IRB/IEC procedures should be...
• Regarding structural similarities to other known compounds, which statement is appropriate?
• Which term is used to describe a method where a participant or investigator is unaware of the treatment assignment?
• What is the purpose of documenting retained body fluids/tissue samples?
• Which statement best describes Quality Assurance in clinical trials?
• Blinding is intended to limit bias arising from knowledge of treatment in which aspects?
• Which term means prevention of disclosure, to other than authorized individuals, of a sponsor's proprietary information or of a subject's identity?
• Which topic specifically covers issues arising when therapy is blinded during a trial?
• Essential Documents are those that demonstrate compliance with which standards?
• When the sponsor discontinues clinical development of an investigational product, who should be notified?
• When may regulatory authorities access audit reports if not routinely requested?
• Which statement best describes subject exclusion criteria?
• If IRB/IEC requires changes to the protocol or consent, what should the sponsor obtain?
• Which statement best describes the tone of the Investigator's Brochure?
• What must be included about the reporting source in expedited ADR reports?
• Which records changes, additions, or corrections made to the Case Report Form after initial data were recorded?
• Which term refers to the operational techniques and activities undertaken within the quality assurance system to verify that requirements for quality of trial-related activities have been fulfilled?
• What is the primary purpose of protection of clinical trial subjects under GCP?
• Phase IV studies may involve which of the following activities?
• What does blinding accomplish in a trial?
• Which concept is primarily supported by documentation that ensures the integrity and accuracy of trial data?
• During participation, what must be provided to the subject regarding consent updates?
• Which document addresses the financial aspects of the trial?
• Phase III is intended to provide an adequate basis for what?
• Regulatory reporting of unexpected serious adverse drug reactions: to whom should these be reported?
• Freely given informed consent must be obtained from every subject prior to clinical trial participation. Which option reflects a key aspect of this requirement?
• Who bears responsibility for implementing and maintaining quality assurance and quality control systems in a trial?
• What is the primary purpose of expedited safety reports in the ICH framework?
• What must be included in the written information provided to subjects regarding payment?
• Investigational products should be manufactured, handled, and stored in accordance with which standard?
• The document that presents the results and interpretations of a clinical trial is called what?
• Which option best describes the Introduction's comprehensive content regarding the product?
• The plan for which variables are collected and how data are gathered is described by which topic?
• In electronic trial data handling, which statement reflects a requirement to protect data integrity?
• Which document records the identity, purity, and strength of investigational products to be used in the trial?
• Which term refers to a study conducted across more than one site to improve generalizability?
• Which statement best describes why trial records are maintained?
• If new information becomes available that may affect a subject's willingness to continue participation, who should be informed?
• In Phase I, which objective is described as Estimation of initial safety and tolerability?
• What must be specified in the protocol regarding access to source data and documents?
• Nonclinical studies focus on which areas to support initial human dose?
• Notification by sponsor and/or investigator to regulatory authorities and IRB/IECs of unexpected serious adverse drug reactions and other safety information is intended for which recipients?
• If a publication policy is not addressed in a separate agreement, what should be established regarding publication of trial results?
• What should the sponsor provide when regulatory requirements require coverage for trial-related injuries?
• For a non-therapeutic trial conducted with consent of the subject's legally acceptable representative, what must the IRB/IEC determine?
• Who is responsible for retaining trial-related essential documents until the sponsor informs they are no longer needed?
• Which description best matches an Impartial Witness in clinical trials?
• Which element describes how long subjects participate and when follow-up occurs, including subsequent trial periods?
• Which statement describes a composite variable?
• Which statement about Categorized Variables is correct?
• What actions should the investigator take to ensure correct use of the investigational product(s) by each subject?
• Regardless of completion, what must be done with clinical trial reports?
• Which statement best describes how missing, unused, and spurious data should be handled in a GCP trial?
• Which bodies may perform inspections of trial data and sites as part of QA activities?
• Source Documents: What is the purpose of source documents in a clinical trial?
• In the Background Information section, which item provides details about the investigational product?
• Which statement best describes a requirement of informed consent?
• Which of the following describes recommended characteristics of an IRB/IEC?
• Which item should the sponsor obtain from the IRB/IEC to confirm GCP compliance?
• The sponsor's procedures should include actions for unused investigational product. Which action is correct?
• In Phase I, what is the primary objective?
• Where should the finalized CRFs be kept after completion and which copy is retained by the sponsor?
• Before trial initiation, which body’s approval or favorable opinion is required for the protocol?
• Which document provides the written information given to trial subjects to support informed consent?
• Phase I is most typically which kind of study?
• During the trial, to whom should the investigator provide documents subject to review?
• Should changes in inclusion and exclusion criteria remain constant during recruitment?
• Which statement best describes the sponsor's responsibilities for the investigational product?
• The Marketing Experience section should identify which information?
• What is the role of an Independent Data-Monitoring Committee (IDMC)?
• Which principle places the rights, safety, and well-being of the trial subjects as the most important considerations, taking precedence over science and society?
• During Monitoring Procedures, after each site visit, what must a monitoring report include?
• Which document records the location and identification of retained body fluids/tissue samples if assays need to be repeated?
• What role do data monitoring committees (DMC/DSMB) play in relation to the clinical database?
• During the trial, which entity monitors safety data continuously?
• Which scenario qualifies as a Serious Adverse Event (SAE)?
• To document that compensation to subjects for trial-related injury will be available, which locations are listed for documentation?
• What term describes a unique identifier assigned by the investigator to each trial subject to protect the subject's identity and used in lieu of the subject's name?
• During participation, what must be provided to the subject when updates to consent are made?
• The sponsor's system for the disposition of unused IP should ensure what?
• Who is responsible for submitting the final report by the investigator to IRB/IEC and to regulatory authorities where required?
• Which document records revisions to trial documents that take effect during the trial?
• Which term is a written description of a trial/study of any therapeutic, prophylactic, or diagnostic agent conducted in human subjects, in which the clinical and statistical description, presentations, and analyses are fully integrated into a single report?
• What term describes a clinical trial conducted according to a single protocol but at more than one site?
• In emergency situations where prior consent is not possible, which statement is correct?
• Which document records treatment allocation and any decoding events and is maintained to support blinding integrity?
• Why is blinded therapy case management included in expedited reporting guidelines?
• Who may vote or provide their opinion in IRB/IEC deliberations and discussions?
• What should the analysis plan address?
• Which statement is included to confirm compliance with protocol and regulatory requirements?
• What is the purpose of the subject identification code list?
• Which statement best describes the purpose of maintaining randomization codes and code-breaking procedures?
• Which description is required to justify the number of subjects enrolled?
• Upon completion of the trial, what should the investigator do?
• Which statement best describes data capture and processing responsibilities in GCP?
• Which topic discusses an integrated summary of trial results?
• Which topic addresses the integrity of data and the validity of computer software used in data handling?
• Which item should be included to provide background by referencing literature and data?
• Phase III aims to complete the information needed to support what?
• 4.5.4 describes what about deviations to eliminate immediate hazards?
• Which statement supports sample size justification?
• If the IRB/IEC withdraws or suspends approval, what should be done?
• Interim analyses may lead to early stopping if which conditions are met?
• Progress Report: How often should the investigator submit written summaries of trial status to the IRB/IEC?
• Which term refers to an individual or body authorized to consent on behalf of a prospective subject?
• What should accompany the communication of new information to the subject to continue participation?
• Which statement best reflects the expected time frame for conducting and completing the trial?
• Which statement best describes sponsor responsibilities related to direct access to source data for monitoring and regulatory inspections?
• When planning trials, what should the sponsor ensure regarding safety and efficacy data?
• In nonclinical pharmacokinetics, which aspect is specifically addressed?
• Which statement describes how monitors should handle standard operating procedures?
• Which document records the normal values and ranges for tests used in the protocol?
• Which statement best describes how all clinical trial information should be treated?
• Which topic is dedicated to the act of reporting study results?
• What must QA/QC ensure about data?
• What is the primary purpose of the Investigator's Brochure?
• The location(s) where trial-related activities are actually conducted are referred to as what?
• The Full Analysis Set is designed to approximate which principle?
• What term describes biomedical studies not performed on human subjects?
• What information should be provided for the physician or dentist responsible for site medical decisions when this person is not the investigator?
• Which document records the destruction of unused investigational products?
• Which item is NOT a data element for expedited reports?
• In multisite trials, what should be specified regarding enrollment?
• Where should signature sheets be maintained?
• Which data are typically included under efficacy data in a clinical trial report?
• What is the key purpose of summarizing the clinical database in the report?
• Which statement correctly lists the minimum criteria for regulatory reporting of ADRs?
• An adverse reaction, the nature or severity of which is not consistent with the applicable product information, is known as what?
• Which term represents all information in original records and certified copies necessary for reconstruction and evaluation of the trial?
• The protocol should include a description of the trial's type or design and what else?
• Which term best describes the process of performing a formal review to ensure compliance with the protocol and SOPs?
• When must pharmacokinetic (PK) impact studies be available?
• Written procedures for handling the investigational product should include which of the following?
• Which document shows the IRB/IEC is constituted in accordance with GCP?
• What should be adequate to support the proposed clinical trial regarding the investigational product?
• Which document confirms that investigational products have been used according to the protocol?
• Which topic is specifically addressed under pharmacokinetic studies?
• In trial planning, which element must be clearly specified in a protocol before the trial begins?
• What is the retention requirement for essential trial documents after a study ends in an ICH region?
• What document provides detailed, written instructions to achieve uniformity of performance of a specific function?
• The investigator should ensure that the investigational product(s) are used only in accordance with what?
• Which concept ensures that trial results are not biased by the method of assigning participants to groups?
• Which statement best describes the efficacy assessment in a clinical trial?
• Which document is used to document that an audit was performed, if available?
• Which statement best describes the packaging objective for investigational product(s)?
• Which term refers to the official review of documents, facilities, and records by a regulatory authority?
• Which statement expresses the requirement that participant safety and well-being take precedence over scientific or societal interests?
• If deviations from the original statistical plan occur, what is required for documentation?
• During trial reviews, special attention should be paid to trials that may include...
• Which term is the formal written summary of the audit findings?
• Which statement about payments to trial subjects is correct?
• What must be maintained for the randomization process and potential code-breaking?
• What must the sponsor verify regarding a subject's consent for direct access to original medical records?
• Which document serves as the formal record that a subject has given informed consent and is used as part of trial data?
• The CRO should implement which of the following quality processes?
• Which document documents chronological enrollment of subjects by trial number?
• Which statement about exploratory trials is true?
• Which role is designated and supervised by the investigator at the trial site to perform critical trial-related procedures?
• Phase III typically includes further exploring which aspect in a broader population?
• What statement best describes the relationship between exploratory and confirmatory trials?
• Which component provides the procedures for eliciting reports of and for recording and reporting adverse events and intercurrent illnesses?
• Which design element helps ensure prognostic factors are balanced across treatment groups?
• What is the recommended timing for reporting SAEs to the sponsor per GCP?
• Which information must be provided for the qualified physician or dentist responsible for all trial-site medical decisions if the physician is not the investigator?
• Under what condition is it recommended to inform the subject's primary physician about participation?
• The investigator should be aware of and comply with which requirements?
• SUSARs require expedited reporting to regulatory authorities within what general timeframe?
• What should be maintained by the IRB/IEC as part of its records?
• What is the term for a report of intermediate results and their evaluation based on analyses performed during the course of a trial?
• Which term is the affirmative decision of the IRB that the trial may be conducted at the site within constraints?
• What entity is responsible for deciding whether a reaction in a trial using an active comparator or placebo should be reported to the manufacturer or to regulatory agencies?
• Essential Documents for the Conduct of a Clinical Trial are intended to permit evaluation of which aspects?
• What should the summary of efficacy data include to support conclusions about a treatment's effect?
• Which of the following best describes the Therapeutic Confirmatory objectives?
• Under what circumstance may the IRB/IEC require that more information be given to subjects beyond standard guidance?
• What is the requirement for retention and archiving of trial records?
• What should be done about deviations from the protocol?
• What term describes all information in original records and certified copies necessary for reconstruction and evaluation of the trial?
• Why must the protocol specify the principal features of the proposed statistical analysis before starting?
• Which statement best describes IRB/IEC record retention duration?
• What payment information must be included in the consent?
• Which body may be established by the sponsor to assess progress, safety data, and critical efficacy variables and to recommend continuation, modification, or termination?
• Which design evaluates two or more treatments simultaneously by varying combinations of treatments?
• Who informs the investigator when essential trial documents no longer need to be retained?
• Which statement best describes the design of a trial in terms of scientific quality?
• Which document provides instructions for handling of investigational products and trial-related materials?
• Which requirement ensures that a trial's conduct aligns with approved procedures?
• 4.5.2 states about deviations without agreement
• Which document confirms the IRB/IEC has reviewed and approved the protocol and includes the official date of approval?
• In superiority trials, which approach most convincingly demonstrates efficacy?
• Who should be informed of storage determinations?
• Which design approaches testing two or more treatments by using different combinations and evaluating potential interactions?
• Which document records shipment dates, batch numbers, and the method of shipment for investigational products and trial-related materials, enabling tracking and accountability?
• Which term is defined as a standard for the design, conduct, performance, monitoring, auditing, recording, analyses, and reporting of clinical trials that provides assurance that the data and reported results are credible and accurate, and that the rights, integrity, and confidentiality of trial subjects are protected?
• All other serious, unexpected ADRs should be filed within how many calendar days after first knowledge?
• Which topic is addressed by the section that covers data integrity and computer software validity?
• A Therapeutic Confirmatory study primarily aims to do which?
• Who is responsible for the medical care and medical decisions for trial subjects?
• What should be signed to confirm agreement to the protocol?
• Which term describes a systematic and independent examination of trial related activities and documents to determine whether they were conducted and the data were recorded, analyzed and accurately reported according to the protocol, sponsor's SOPs, GCP, and applicable regulatory requirements?
• If a deviation is implemented to eliminate an immediate hazard, what must be done?
• Which Phase I consideration relates to clearance and potential drug-drug interactions?
• In Phase II, what is the primary consideration for dosing and regimen?
• Which is NOT a standard toxicology heading under nonclinical studies?
• Who must sign and date the written informed consent prior to participation?
• Who is the person responsible for the conduct of the clinical trial at a trial site?
• Which term is used for an ADR that is not described in the product labeling or Investigator's Brochure?
• Which document lists all subjects enrolled and is kept confidential for potential follow-up?
• Who keeps the Subject Identification Code List, a confidential list of names of all subjects allocated to trial numbers and the ability to reveal identity when needed?
• May an IRB/IEC invite nonmembers with expertise for assistance?
• Which statement correctly describes the Full Analysis Set?
• When preparing the clinical study report, what should the summary of the clinical database include?
• Which records document that consent is obtained in accordance with GCP and protocol and dated prior to participation of each subject in trial, and also document direct access permission?
• Which statement is not described as part of the Investigator's Brochure's purpose?
• What follow-up is advised for subjects who withdraw from treatment?
• Which design assigns a sequence of two or more treatments to the same participant, allowing them to serve as their own control?
• If a subject withdraws prematurely, what should the investigator do regarding the reasons?
• Under what conditions may expedited review be provided for minor changes in ongoing trials?
• What documentation certifies the identity, purity, and strength of investigational products to be used in the trial?
• What do you call a clinical trial conducted according to a single protocol but at more than one site?
• Ethical considerations in a clinical trial include which of the following?
• Which design is defined as evaluating two or more treatments simultaneously through varying combinations and possible interactions?
• In emergency enrollment where prior consent is not possible, which statement is NOT correct?
• Which document is listed as being located at both the investigator/institution and sponsor locations to reflect agreement on protocol/amendments and CRF?
• Who is responsible for initiating, managing, and financing a clinical trial?
• When a CRO has assumed trial-related duties, to whom do references to the sponsor apply?
• The investigator should be thoroughly familiar with the appropriate use of the investigational products as described in which sources?
• Which factors determine the extent and nature of monitoring?
• The brochure's purpose supports investigators in assessing risk-benefit for which aspect?
• One of the objectives of the ICH E8 document is to present an overview of the ICH clinical safety and efficacy documents and facilitate access to guidance pertinent to clinical trials. Which option best captures this objective?
• Which type of trial is primarily intended to provide firm evidence of efficacy or safety?
• When selecting subjects for a Phase IV study, which factors should be considered?
• Which document demonstrates compliance with labeling regulations and the appropriateness of instructions provided to subjects?
• Which term refers to the written evaluation provided by the sponsor's auditor summarizing the audit results?
• What should the Title Page potentially include according to the guidelines?
• Under which circumstances may protocol deviations or changes be initiated without prior IRB/IEC approval?
• What is the purpose of the Subject Identification Code List?
• Which statement describes investigator obligations under 5.6.2 a-d?
• Which data are considered source data in a GCP trial and should be recorded directly on the Case Report Form (CRF)?
• Which document records that amendments and/or revisions have been subject to IRB/IEC review and were given approval/favorable opinion, and identifies the version number and date of the documents?
• Who submits the final report by the investigator to IRB/IEC and, where applicable, to regulatory authorities?
• Which term is a declaration of confirmation by the auditor that an audit has taken place?
• Which statement best reflects the Marketing Experience section?
• During the trial, what should the investigator provide to the IRB/IEC?
• Phase IV objectives may include which of the following?
• What does the IRB/IEC determine as appropriate for continuing review?
• How should the sponsor inform investigators about the need for record attention?
• If a sponsor transfers trial-related duties to a CRO, who retains ultimate responsibility for the quality and integrity of the trial data?
• Which criterion justifies early termination of a trial?
• Which parties are responsible for maintaining documentation of regulatory authorities' authorization/approvals/notifications for protocol amendments and other documents?
• What presentation is useful for safety and efficacy data across multiple trials by indications or subgroups?
• What is the primary purpose of QA/QC systems in GCP?
• Equivalence and non-inferiority trials are divided into two major objective-based categories according to their goals. Which pair describes these categories?
• In a clinical trial, which entity takes responsibility for initiation, management, and financing of the trial?
• Which term describes the process of assigning trial subjects to treatment or control groups using chance to reduce bias?
• What should be addressed in the nonclinical pharmacokinetics section?
• Which term best describes documents which individually and collectively permit evaluation of the conduct of a study and the quality of the data produced?
• In a dose-ranging program, what is the primary objective?
• Which statement best reflects a monitor's qualification responsibilities?